

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1634

KUDARAVALLI ET AL.

Examiner: Pohnert, Steven C

APPLICATION NO: 10/529,613

FILED: MARCH 30, 2005

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING
IMMUNOSUPPRESSANT THERAPY

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



Leslie Fischer
Attorney for Applicants
Reg. No. 58,393

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9308

Date: 2/26/09